The fact remains that the Phylomer "platform" is vastly broader than simply a screening base for endosome penetration peptides.
While the technology is hugely valuable, if PYC can arrange a commercial deal, it would be best to "spin off" this technology in a separate business unit and continuing on to apply the Phylomer technologies to other (diverse) problems.
PYC has a number of "short game" options:
- Immunology
- Cell Apotosis
- Endosomal Escape Trap
There are also a large number of "long game" opportunities.
This "snowball" could roll down hill for a very long time (to reference WB).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.045(3.13%) |
Mkt cap ! $813.6M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.46 | $1.36 | $314.1K | 222.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 330 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 12708 | 2 |
View Market Depth
| Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |